Overview

Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if rituximab is a safe and effective therapy for steroid-refractory chronic graft versus host disease (GVHD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Brigham and Women's Hospital
Treatments:
Rituximab